1. Home
  2. PLYX

as of 04-13-2026 4:00pm EST

$6.17
+$0.49
+8.63%
Stocks Health Care Biotechnology: Pharmaceutical Preparations Nasdaq

Polaryx Therapeutics Inc is a clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, disease-modifying therapies for rare, pediatric LSDs. Its therapeutic approach focuses on treating the underlying pathophysiology of these diseases and addressing unmet needs. The company's therapeutic pipeline includes PLX-200, PLX-300, and PLX-100, which are orally available small-molecule drug candidates designed to address core pathological mechanisms common to LSDs. The Company has one reportable segment: lysosomal storage disorders. The lysosomal storage disorders segment consists of the Company's costs associated with the preclinical and clinical development of the Company's product candidates.

Founded: 2014 Country:
United States
United States
Employees: N/A City: PARAMUS
Market Cap: 271.8M IPO Year: N/A
Target Price: $10.00 AVG Volume (30 days): 545.2K
Analyst Decision: Strong Buy Number of Analysts: 1
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: N/A EPS Growth: N/A
52 Week Low/High: $2.20 - $9.18 Next Earning Date: 05-22-2026
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A
P/E Ratio: N/A Index: N/A
Free Cash Flow: N/A FCF Growth: N/A

Share on Social Networks: